PDL BioPharma, Inc.
(NASDAQ : PDLI)

( )
PDLI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.62%190.361.2%$564.46m
GILDGilead Sciences, Inc.
-0.52%70.550.9%$491.72m
BIIBBiogen Inc.
-1.73%313.551.3%$448.17m
CELGCelgene Corporation
-0.87%69.631.2%$426.13m
ILMNIllumina, Inc.
-0.95%308.233.5%$394.71m
REGNRegeneron Pharmaceuticals, Inc.
-1.41%337.292.6%$283.70m
VRTXVertex Pharmaceuticals Incorporated
-3.36%164.581.9%$265.75m
ALXNAlexion Pharmaceuticals, Inc.
-2.03%116.112.0%$195.76m
AAgilent Technologies, Inc.
-1.32%63.491.5%$175.37m
EXASExact Sciences Corporation
-1.38%68.4525.3%$145.96m
LGNDLigand Pharmaceuticals Incorporated
-0.42%147.8023.3%$142.63m
SRPTSarepta Therapeutics, Inc.
-4.09%111.9916.4%$134.89m
ECYTEndocyte, Inc.
-0.21%23.532.0%$121.26m
INCYIncyte Corporation
0.66%64.152.5%$116.78m
NKTRNektar Therapeutics
0.80%37.655.6%$109.74m

Company Profile

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.